Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.
Freeman SD. et al, (2023), Blood
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2023), Nat Commun, 14
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Macaulay VM. et al, (2023), Br J Cancer
Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1.
Sugiyarto G. et al, (2023), J Immunother Cancer, 11
Early phase antitumour clinical trials and palliative medicine.
Virani F. et al, (2023), BMJ Support Palliat Care
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Charles Coombes R. et al, (2023), Nat Commun, 14
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM. et al, (2023), Cancer Cell, 41, 1222 - 1241.e7
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R. et al, (2023), Br J Cancer, 129, 38 - 45
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Nicholson BD. et al, (2023), Lancet Oncol